Skip to main content

Invasive Candidiasis

8
Pipeline Programs
6
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
3
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
3 programs
1
1
1
CaspofunginPhase 41 trial
caspofungin acetatePhase 31 trial
Caspofungin acetatePhase 21 trial
Active Trials
NCT01045798Terminated15Est. Apr 2012
NCT00250432Completed204Est. Mar 2008
NCT00520234Completed222Est. Mar 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
1
1
1
CaspofunginPhase 4
caspofungin acetatePhase 3
Caspofungin acetatePhase 2
Astellas
AstellasChina - Shenyang
2 programs
1
1
MicafunginPhase 31 trial
MicafunginPhase 11 trial
Active Trials
NCT00607763Completed9Est. Oct 2009
NCT00189709Completed24Est. Jul 2006
Pfizer
PfizerNEW YORK, NY
1 program
Preemptive Therapy with AnidulafunginN/A1 trial
Active Trials
NCT00672841Completed64Est. Jan 2011
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
therapy durationN/A1 trial
Active Trials
NCT05763251Recruiting420Est. Jun 2032
Scynexis
ScynexisJERSEY CITY, NJ
1 program
IbrexafungerpPHASE_31 trial
Active Trials
NCT03059992Completed233Est. Aug 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
MSDCaspofungin
ScynexisIbrexafungerp
MSDcaspofungin acetate
AstellasMicafungin
MSDCaspofungin acetate
AstellasMicafungin
Allergy Therapeuticstherapy duration
PfizerPreemptive Therapy with Anidulafungin

Clinical Trials (8)

Total enrollment: 1,191 patients across 8 trials

NCT00520234MSDCaspofungin

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

Start: Aug 2007Est. completion: Mar 2010222 patients
Phase 4Completed
NCT03059992ScynexisIbrexafungerp

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Start: Apr 2017Est. completion: Aug 2023233 patients
Phase 3Completed
NCT00250432MSDcaspofungin acetate

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Start: Jan 2006Est. completion: Mar 2008204 patients
Phase 3Completed
NCT00189709AstellasMicafungin

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

Start: Aug 2004Est. completion: Jul 200624 patients
Phase 3Completed
NCT01045798MSDCaspofungin acetate

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)

Start: Dec 2010Est. completion: Apr 201215 patients
Phase 2Terminated
NCT00607763AstellasMicafungin

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Start: Oct 2007Est. completion: Oct 20099 patients
Phase 1Completed
NCT05763251Allergy Therapeuticstherapy duration

Comparison of Uncomplicated Candidemia Therapy Duration in Children

Start: Sep 2023Est. completion: Jun 2032420 patients
N/ARecruiting
NCT00672841PfizerPreemptive Therapy with Anidulafungin

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Start: Jun 2008Est. completion: Jan 201164 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,191 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.